Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment
- Friday, February 25, 2022, 7:06
- Finance
- Add a comment
NEW HAVEN, Conn. and NEW YORK, Feb. 25, 2022 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive…
About the Author
adminasapcorp has written 41546 stories on this site.